Jonathan D Fuchs

Summary

Affiliation: San Francisco General Hospital
Country: USA

Publications

  1. pmc Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants
    Jonathan D Fuchs
    San Francisco Department of Public Health, San Francisco, CA 94102, USA
    J Acquir Immune Defic Syndr 63:259-62. 2013
  2. ncbi request reprint Negative social impacts among volunteers in an HIV vaccine efficacy trial
    Jonathan Fuchs
    AIDS Office, San Francisco Department of Public Health, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 46:362-8. 2007
  3. pmc Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial
    Jonathan Fuchs
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA 94102, USA
    J Infect Dis 201:1164-8. 2010
  4. pmc Lessons drawn from recent HIV vaccine efficacy trials
    Jonathan D Fuchs
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA 94102, USA
    J Acquir Immune Defic Syndr 55:S128-31. 2010
  5. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
  6. ncbi request reprint A shot or a pill: exploring biomedical approaches to HIV prevention
    Jonathan Fuchs
    Focus 19:1-5. 2004
  7. pmc Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial
    David V Jobes
    VaxGen, Inc, South San Francisco, California 94080, USA
    AIDS Res Hum Retroviruses 22:968-78. 2006
  8. pmc Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial
    Connie Celum
    Department of Global Health, University of Washington, Seattle, WA, USA
    Lancet 371:2109-19. 2008

Detail Information

Publications8

  1. pmc Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants
    Jonathan D Fuchs
    San Francisco Department of Public Health, San Francisco, CA 94102, USA
    J Acquir Immune Defic Syndr 63:259-62. 2013
    ..As key stakeholders, currently enrolled trial participants can offer vital input about emerging prevention technologies that may affect the design of future HIV vaccine and nonvaccine prevention trials...
  2. ncbi request reprint Negative social impacts among volunteers in an HIV vaccine efficacy trial
    Jonathan Fuchs
    AIDS Office, San Francisco Department of Public Health, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 46:362-8. 2007
    ..Describe the negative social impacts (NSIs) and their predictors in an HIV vaccine efficacy trial...
  3. pmc Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial
    Jonathan Fuchs
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA 94102, USA
    J Infect Dis 201:1164-8. 2010
    ..The observed regional variation in the clinical and virologic efficacy of acyclovir for HSV suppression warrants further evaluation of determinants of responses to acyclovir. (ClinicalTrials.gov identifier: NCT00076232.)...
  4. pmc Lessons drawn from recent HIV vaccine efficacy trials
    Jonathan D Fuchs
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA 94102, USA
    J Acquir Immune Defic Syndr 55:S128-31. 2010
    ..Future efficacy trial designs may incorporate novel, partially effective prevention strategies. Although greater in size and complexity, these trials may offer unique opportunities to explore synergies with vaccines under study...
  5. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
    ..The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels...
  6. ncbi request reprint A shot or a pill: exploring biomedical approaches to HIV prevention
    Jonathan Fuchs
    Focus 19:1-5. 2004
  7. pmc Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial
    David V Jobes
    VaxGen, Inc, South San Francisco, California 94080, USA
    AIDS Res Hum Retroviruses 22:968-78. 2006
    ..Our results suggest significant differences on the evolutionary dynamics of these strains. We then discuss the implications of these results for vaccine development...
  8. pmc Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial
    Connie Celum
    Department of Global Health, University of Washington, Seattle, WA, USA
    Lancet 371:2109-19. 2008
    ..We investigated whether HSV-2 suppression with aciclovir would reduce the risk of HIV-1 acquisition...